SCHEMBL214720

SCHEMBL214720

Cc1nc(NC(=O)c2c(C(N)=O)ncn2-c2c(Cl)cccc2Cl)[nH]c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 1/20 0.35
MAOB P27338 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
CHRNA7 P36544 3/20 0.35
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPK1 P28482 1/20 0.33
SLC9A1 P19634 2/20 0.32
ABL1 P00519 1/20 0.32
CSNK2A2 P19784 1/20 0.32
KDR P35968 1/20 0.32
PLK1 P53350 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
ALDH1A1 P00352 1/20 0.32
EPHB3 P54753 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216012 0.93 KDM4E (0.36) MAOBADORA2AADORA2BADORA1CHRNA7
SCHEMBL214015 0.80 MAOB (0.53) MAOBADORA2AADORA2BADORA1SMN1; SMN2
SCHEMBL213884 0.77 HCAR1 (0.33) HCAR1KDM4EMAPTNPC1RAB9A
SCHEMBL214391 0.76 RPS6KA2 (0.45) HPGDSMN1; SMN2KDRKDM4EALDH1A1
SCHEMBL213579 0.74 LMNA (0.43) SMN1; SMN2MAPK1ABL1KDRPLK1
SCHEMBL214580 0.74 TOP2A (0.39)
SCHEMBL214529 0.74 HRH3 (0.42) MAPK1ABL1KDREPHB4MAPT
SCHEMBL215459 0.72 CHEK2 (0.46) SMN1; SMN2MAPK1ABL1KDRKDM4E
SCHEMBL214609 0.72 MAOB (0.46) MAOBADORA2AADORA2BADORA1HPGD
SCHEMBL214859 0.72 CHEK2 (0.47) MAPK1ABL1KDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 HCAR1 4180/4885MAOB 3387/4885ADORA2A 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.